

Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028

<https://marketpublishers.com/r/GC4618CA89A4EN.html>

Date: July 2023

Pages: 124

Price: US\$ 4,950.00 (Single User License)

ID: GC4618CA89A4EN

Abstracts

The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Market growth is driven by factors such as the increased number of diabetic patients above the age of 65 years and government initiatives for disease diagnosis. On the other hand, challenges associated with the glycated albumin assay market, like unfavorable reimbursement scenarios, are the major factors restricting market growth.

“The prediabetic segment accounted for the highest growth rate in the glycated albumin assay market, by application, during the forecast period”

The glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. In 2022, the prediabetes segment accounted for the highest glycated albumin assay market growth rate. The increasing focus on the prevention of lifestyle diseases like diabetes, growth in the number of diagnostic laboratories, and improving healthcare infrastructure in emerging countries are major factors contributing to this segment's growth.

“The diagnostic laboratories segment accounted for the highest growth in the glycated albumin assay market, by end-user, during the forecast period”

The glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories, and other end-user based on end users. In 2022, the

diagnostic laboratories segment accounted for the highest glycated albumin assay market growth rate. Diagnostics laboratories often offer cost-effective and convenient testing options for healthcare providers and patients. By outsourcing glycated albumin testing to diagnostics laboratories, healthcare providers can avoid the need for in-house testing facilities and associated costs. Additionally, patients can visit diagnostics laboratories for their glycated albumin assays without the need for hospitalization or specialized clinic visits. The cost-effectiveness and convenience of diagnostics laboratories make them an attractive option, leading to increased demand and segment growth.

“Asia Pacific: The fastest-growing region in glycated albumin assay market”

The North American, European, Asia Pacific, Latin American, Middle Eastern, and African regions make up the major segments of the worldwide glycated albumin assay market. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The glycated albumin assay market in this region is expanding as a result of an increase in diabetes awareness programmes and favourable government healthcare policies.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6% , and the Middle East & Africa – 4%

List of Companies Profiled in the Report:

Asahi Kasei Corporation (Japan)

Beijing Strong Biotechnologies, Inc. (China)

Diazyme Laboratories, Inc. (US)

DxGen Corp. (South Korea)

Weldon Biotech, Inc.(India)

Hzymes Biotech (China)

Research Coverage:

This report provides a detailed picture of the global glycated albumin assay market. It aims at estimating the size and future growth potential of the market across different segments, such as application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profile and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall glycated albumin assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKET SCOPE
 - 1.3.1 MARKET SEGMENTATION
 - 1.3.2 GEOGRAPHICAL SCOPE
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
 - FIGURE 1 GLYCATED ALBUMIN ASSAY MARKET: RESEARCH DESIGN
 - METHODOLOGY
 - 2.2.1 SECONDARY DATA
 - 2.2.1.1 Key data from secondary sources
 - 2.2.2 PRIMARY DATA
 - 2.2.2.1 Primary sources
 - 2.2.2.2 Key data from primary sources
 - 2.2.2.3 Key industry insights
 - 2.2.2.4 Breakdown of primary interviews
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 - FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.3 MARKET SIZE ESTIMATION
 - 2.3.1 BOTTOM-UP APPROACH
 - 2.3.1.1 Approach 1: Company revenue estimation approach
 - FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 - 2.3.1.2 Approach 2: Primary interviews

2.3.1.3 Growth forecast

2.3.1.4 Glycated Albumin Assay Market: CAGR Projections

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.3.2 TOP-DOWN APPROACH

FIGURE 6 GLYCATED ALBUMIN ASSAY MARKET: TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY

FIGURE 7 DATA TRIANGULATION METHODOLOGY

2.5 MARKET SHARE ANALYSIS

2.6 STUDY ASSUMPTIONS

2.7 STUDY LIMITATIONS

2.8 GROWTH RATE ASSUMPTIONS

2.9 RISK ASSESSMENT

2.9.1 GLYCATED ALBUMIN ASSAY MARKET: RISK ASSESSMENT ANALYSIS

2.10 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

FIGURE 8 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 9 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 10 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

4.1 GLYCATED ALBUMIN ASSAY MARKET OVERVIEW

FIGURE 11 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET

4.2 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028

FIGURE 12 TYPE 2 DIABETES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

4.3 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028

FIGURE 13 HOSPITALS AND DIABETIC CARE CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

4.4 GLYCATED ALBUMIN ASSAY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES

FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 15 GLYCATED ALBUMIN ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Rising incidence of diabetes

FIGURE 16 PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION, 2021 VS. 2045 (USD MILLION)

TABLE 1 TOTAL HEALTH EXPENDITURE (USD) FOR DIABETES (20–79 YEARS), BY COUNTRY (2021)

5.2.1.2 Growing focus on early detection of diabetes

5.2.1.3 Increase in age-associated diabetic ailments

5.2.2 RESTRAINTS

5.2.2.1 Unfavorable reimbursement scenario

5.2.3 OPPORTUNITIES

5.2.3.1 Rising investments in life sciences research

5.2.4 CHALLENGES

5.2.4.1 Stringent regulatory requirements for diagnostic products

5.2.4.2 Presence of alternative tests

5.3 PRICING ANALYSIS

TABLE 2 AVERAGE SELLING PRICE OF GLYCATED ALBUMIN ASSAY PRODUCTS

5.4 PATENT ANALYSIS

FIGURE 17 PATENT ANALYSIS FOR GLYCATED ALBUMIN ASSAYS (JANUARY 2013–DECEMBER 2022)

5.4.1 GLYCATED ALBUMIN ASSAY MARKET: LIST OF MAJOR PATENTS

5.5 VALUE CHAIN ANALYSIS

FIGURE 18 GLYCATED ALBUMIN ASSAY MARKET: MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASES

5.6 SUPPLY CHAIN ANALYSIS

FIGURE 19 GLYCATED ALBUMIN ASSAY MARKET: SUPPLY CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

FIGURE 20 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM MAP

5.7.1 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM ROLE

5.8 PORTER'S FIVE FORCES ANALYSIS

TABLE 3 GLYCATED ALBUMIN ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS

5.8.1 THREAT OF NEW ENTRANTS

- 5.8.2 THREAT OF SUBSTITUTES
- 5.8.3 BARGAINING POWER OF BUYERS
- 5.8.4 BARGAINING POWER OF SUPPLIERS
- 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.9 REGULATORY LANDSCAPE
 - TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - TABLE 7 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - 5.9.1 NORTH AMERICA
 - 5.9.1.1 US
 - 5.9.1.2 Canada
 - 5.9.2 EUROPE
 - TABLE 8 EUROPE: CLASSIFICATION OF DEVICES
 - 5.9.3 ASIA PACIFIC
 - 5.9.3.1 China
 - 5.9.3.2 Japan
 - 5.9.3.3 India
 - 5.9.4 LATIN AMERICA
 - 5.9.4.1 Brazil
 - 5.9.4.2 Mexico
 - 5.9.5 MIDDLE EAST
 - 5.9.6 AFRICA
- 5.10 TRADE ANALYSIS
 - 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
 - 5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
 - 5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
- 5.11 TECHNOLOGY ANALYSIS
- 5.12 KEY CONFERENCES AND EVENTS
 - TABLE 9 DETAILED LIST OF CONFERENCES AND EVENTS (2022?2023)
- 5.13 PESTLE ANALYSIS
- 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
 - FIGURE 21 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHIFT MAPPING

5.15 KEY STAKEHOLDERS AND BUYING CRITERIA

5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GLYCATED ALBUMIN ASSAYS

TABLE 10 GLYCATED ALBUMIN ASSAY MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)

5.15.2 BUYING CRITERIA

FIGURE 23 GLYCATED ALBUMIN ASSAY MARKET: KEY BUYING CRITERIA

TABLE 11 KEY BUYING CRITERIA FOR GLYCATED ALBUMIN ASSAYS, BY END USER

5.16 CASE STUDY ANALYSIS

FIGURE 24 CASE STUDY ANALYSIS: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION

6.1 INTRODUCTION

TABLE 12 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

6.2 TYPE 2 DIABETES

6.2.1 DIETARY AND LIFESTYLE CHANGES TO CONTRIBUTE TO MARKET GROWTH

TABLE 13 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 2 DIABETES, BY REGION, 2021–2028 (USD MILLION)

6.3 PREDIABETES

6.3.1 INSULIN RESISTANCE AND RISING CASES OF PREDIABETES TO DRIVE MARKET

TABLE 14 GLYCATED ALBUMIN ASSAY MARKET FOR PREDIABETES, BY REGION, 2021–2028 (USD MILLION)

6.4 TYPE 1 DIABETES

6.4.1 INCREASING INCIDENCE AMONG CHILDREN AND ADOLESCENTS TO SUPPORT MARKET GROWTH

TABLE 15 INCIDENCE OF TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS AGED 0 TO 19, BY REGION, 2021 (THOUSANDS)

TABLE 16 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 1 DIABETES, BY REGION, 2021–2028 (USD MILLION)

7 GLYCATED ALBUMIN ASSAY MARKET, BY END USER

7.1 INTRODUCTION

TABLE 17 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

7.2 HOSPITALS AND DIABETES CARE CENTERS

7.2.1 ABILITY TO OFFER RAPID RESULTS IN ACCESSIBLE SETTING TO DRIVE MARKET

TABLE 18 GLYCATED ALBUMIN ASSAY MARKET FOR HOSPITALS AND DIABETES CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)

7.3 DIAGNOSTIC LABORATORIES

7.3.1 RISING OUTSOURCING OF RESEARCH ACTIVITIES FOR COST REDUCTION TO DRIVE MARKET

TABLE 19 GLYCATED ALBUMIN ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

7.4 OTHER END USERS

TABLE 20 GLYCATED ALBUMIN ASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)

8 GLYCATED ALBUMIN ASSAY MARKET, BY REGION

8.1 INTRODUCTION

TABLE 21 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)

8.2 NORTH AMERICA

FIGURE 25 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT

TABLE 22 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 23 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 24 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2.1 US

8.2.1.1 High healthcare expenditure for diabetes treatment & diagnosis to drive market

TABLE 25 US: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 26 US: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2.2 CANADA

8.2.2.1 Rising awareness of early diabetes detection to support market growth

TABLE 27 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029

TABLE 28 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 29 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2.3 NORTH AMERICA: RECESSION IMPACT

8.3 EUROPE

TABLE 30 PREVALENCE OF DIABETES IN EUROPE, 2021 VS. 2045

TABLE 31 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 32 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 33 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.1 GERMANY

8.3.1.1 Provision of healthcare coverage for technologically advanced assays to drive market

TABLE 34 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 35 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.2 UK

8.3.2.1 Rising geriatric population and diabetes-associated ailments to drive market

TABLE 36 UK: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 37 UK: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.3 FRANCE

8.3.3.1 Increasing R&D expenditure for product commercialization to drive market

TABLE 38 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 39 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.4 ITALY

8.3.4.1 Improvements in healthcare infrastructure to support market growth

TABLE 40 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 41 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.5 SPAIN

8.3.5.1 Rising incidence of diabetes among senior women to support market growth

TABLE 42 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 43 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.6 REST OF EUROPE

TABLE 44 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 45 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.3.7 EUROPE: RECESSION IMPACT

8.4 ASIA PACIFIC

FIGURE 26 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT

TABLE 46 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 47 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 48 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.4.1 CHINA

8.4.1.1 Improving healthcare infrastructure to propel market

TABLE 49 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 50 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.4.2 JAPAN

8.4.2.1 Universal healthcare reimbursement policy to support market growth

TABLE 51 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 52 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.4.3 INDIA

8.4.3.1 implementation of favorable government initiatives to drive market

TABLE 53 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 54 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.4.4 REST OF ASIA PACIFIC

TABLE 55 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 56 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.4.5 ASIA PACIFIC: RECESSION IMPACT

8.5 LATIN AMERICA

8.5.1 RISING GOVERNMENT-FUNDED PROGRAMS FOR ACCURATE AND EARLY DISEASE DIAGNOSIS TO DRIVE MARKET

TABLE 57 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 58 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.5.2 LATIN AMERICA: RECESSION IMPACT

8.6 MIDDLE EAST & AFRICA

8.6.1 EXPANSION OF KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH

TABLE 59 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS

FIGURE 27 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHARE ANALYSIS

9.3 MARKET SHARE ANALYSIS

9.3.1 GLYCATED ALBUMIN ASSAY MARKET

FIGURE 28 GLYCATED ALBUMIN ASSAY MARKET SHARE, BY KEY PLAYER (2022)

TABLE 61 GLYCATED ALBUMIN ASSAY MARKET: INTENSITY OF COMPETITIVE RIVALRY

9.4 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX

9.4.1 STARS

9.4.2 EMERGING LEADERS

9.4.3 PERVASIVE PLAYERS

9.4.4 PARTICIPANTS

FIGURE 29 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX (2022)

9.5 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR

STARTUPS/SMES (2022)

9.5.1 PROGRESSIVE COMPANIES

9.5.2 STARTING BLOCKS

9.5.3 RESPONSIVE COMPANIES

9.5.4 DYNAMIC COMPANIES

FIGURE 30 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)**9.6 COMPETITIVE BENCHMARKING**

9.6.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS

FIGURE 31 GLYCATED ALBUMIN ASSAY MARKET: PRODUCT AND REGIONAL FOOTPRINT ANALYSIS**TABLE 62 GLYCATED ALBUMIN ASSAY MARKET: COMPETITIVE EVALUATION OF KEY PLAYERS****TABLE 63 GLYCATED ALBUMIN ASSAY MARKET: COMPANY PRODUCT FOOTPRINT****TABLE 64 GLYCATED ALBUMIN ASSAY MARKET: COMPANY REGIONAL FOOTPRINT****10 COMPANY PROFILES**

(Business overview, Products offered, Recent Developments, MNM view)*

10.1 KEY PLAYERS

10.1.1 ASAHI KASEI CORPORATION

TABLE 65 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW**FIGURE 32 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)**

10.1.2 BEIJING STRONG BIOTECHNOLOGIES, INC.

TABLE 66 BEIJING STRONG BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW**FIGURE 33 BEIJING STRONG BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)**

10.1.3 DIAZYME LABORATORIES, INC.

TABLE 67 DIAZYME LABORATORIES, INC.: COMPANY OVERVIEW

10.1.4 DXGEN CORP.

TABLE 68 DXGEN CORP: COMPANY OVERVIEW

10.1.5 WELDON BIOTECH, INC.

TABLE 69 WELDON BIOTECH, INC.: COMPANY OVERVIEW

10.1.6 HZYMES BIOTECH

TABLE 70 HZYMES BIOTECH: COMPANY OVERVIEW

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX

11.1 DISCUSSION GUIDE

11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

11.3 CUSTOMIZATION OPTIONS

11.4 RELATED REPORTS

11.5 AUTHOR DETAILS

I would like to order

Product name: Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/GC4618CA89A4EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC4618CA89A4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970